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1328NYHA functional class I, and MR severity by TEE
(assessed by an independent core-lab) has remained
mild (Figure 1, Online Video 3) with an EROA ¼
0.09 cm2 and RVol ¼ 12 ml/beat.
Transcatheter therapies for treatment of cardiac
diseases are increasingly being adopted, particularly
for high-risk surgical patients. This case demonstrates
the feasibility of percutaneous transseptal delivery of
a “surgical-like” adjustable posterior annuloplasty
Dacron band. Cardioband implantation was associ-
ated with substantial reduction of the septolateral
annular dimension, to an extent comparable to that
obtained by surgical annuloplasty. Clinical studies are
warranted to appraise its risk–beneﬁt balance in ab-
solute terms and in comparison, or in combination,
with other transcatheter mitral valve repair strategies.*Francesco Maisano, MD
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APPENDIX For the supplemental videos, please see the online
version of this article.Experience With an
Innovative New Food
and Drug Administration
Pathway for
First-in-Human Studies
Carotid Baroreceptor Ampliﬁcation
for Resistant HypertensionIt has now been over 2 years since JACC: Car-
diovascular Interventions published the Bertog et al.
state-of-the-art review (1) “Renal Denervation for
Hypertension,” detailing the physiological rationale
for renal denervation (RDN) in resistant hyperten-
sion. Since then, interest in the ﬁeld of sympathetic
modulation soared exponentially but was quickly
brought back to earth with the publication of the
SYMPLICITY HTN-3 (Renal Denervation in Patients
With Uncontrolled Hypertension) study, the only
blinded, randomized study of RDN, which failed to
meet its pre-speciﬁed efﬁcacy endpoint (2). It is
currently unclear whether the results of SYMPLICITY-
3 were due to technically inadequate ablation,
underestimation of additional beneﬁts from study-
mediated medical therapy, or inappropriate patient
selection, or whether the initial hypothesis was in
some way ﬂawed. We believe the former issues are
likely in play and that the optimistic conclusions from
Bertog et al. (1) for RDN will ultimately hold true.
However, given the unmet need of alternative ther-
apeutic options for resistant hypertension, explora-
tion for alternative methods to modulate sympathetic
tone is warranted.
It is well known that the carotid baroreﬂex is an
important feedback loop for hemodynamic balance
and adrenergic tone. Carotid baroreceptors are known
to activate by pulsatile stretch rather than pressure
and the receptor response decays when stimulation
from stretch is constant, explaining why hemody-
namic changes after carotid stenting are generally
transient (3). A study of electrical baroreceptor stim-
ulation for treatment of resistant hypertension via a
surgical implant adjacent to the carotid sinus was
successful in lowering blood pressure (BP), however,
it did not meet its pre-speciﬁed procedural safety
endpoint (4). Although effective, this surgical risk
may not be acceptable for most resistant hyperten-
sive patients. Combining knowledge of baroreceptor
physiology with known pressure–strain relationships
for pressurized tubular structures, we hypothesized
that certain geometric changes of the carotid bulb
FIGURE 1 Mechanical Carotid Baroreceptor Ampliﬁcation
(A) Positioned in the internal carotid artery, MobiusHD modiﬁes axial geometry by inducing a noncircular cross-sectional area that increases the
relative radius of the carotid sinus in the window between struts. This results in dramatic increases in carotid wall strain without impacting
pulsatility. (B) The right carotid artery before, on the left, and after, on the right, successful deployment of a MobiusHD. The central cartoon
depiction of the carotid artery recreates the relationship between the device struts and adjacent baroreceptor and carotid sinus nerves. The
asterisks highlight the radio-opaque markers on the superior and inferior crown apices of the MobiusHD.
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1329can create sustainable ampliﬁcation of baroreceptor
feedback. This theory led to development of an
intravascular prosthesis that alters carotid bulb ge-
ometry with the intent of increasing wall stretch.
Speciﬁcally, the device increases the relative radius
of the carotid sinus in the window between struts
(Figure 1) resulting in dramatic increases in carotid
bulb strain. Subsequent extensive pre-clinical studies,
ﬁnite element ﬂow analysis, and animal and cadav-
eric studies led to approval for a ﬁrst-in-human study
by the United States Food and Drug Administration
(FDA) Early Feasibility Medical Device Clinical
Studies Program (IDE#G130013) entitled the CALM-
FIM_US (Controlling and Lowering Blood Pressure
With the MobiusHD) study. This study was 1 of 9
studies to be approved for this novel FDA pathway,
and we believe this program reﬂects a positive and
noteworthy change in the bureaucratic landscape for
U.S. innovation. The fast-track model allowed us to
perform the ﬁrst-in-human case in the United Statesbefore the mirror European protocols could be
initiated.
The ﬁrst-in-human case was performed following
approval by the Emory University Institutional Review
Board and involved a 56-year-old African-American
man with a 30-year history of hypertension, type 2
diabetes mellitus, obesity, and a negative workup
for secondary hypertension. He had failed to res-
pond to an optimally dosed stable regimen of 5
antihypertensive agents, including amlodipine, car-
vedilol, lisinopril, hydralazine, and furosemide. His
BP was monitored daily at home for 2 weeks during
an initial screening period, with a mean value of
159/99 mm Hg. This 2-week period included medi-
cation adherence monitoring via medication diary
and daily self-recording of BP. An ofﬁce based BP
measurement after the 2-week screening period
was 164/93 mm Hg, with a baseline heart rate of 57
beats/min. Duplex ultrasound andmagnetic resonance
angiography performed in preparation for carotid
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1330baroreﬂex sensitivity did not reveal carotid athero-
sclerosis. Carotid massage testing demonstrated no
evidence of hypersensitivity, and orthostatic maneu-
vers demonstrated normal response.
Carotid angiography conﬁrmed the absence of
atherosclerosis and pre-speciﬁed carotid size param-
eters compatible with the study device. The device
was placed without incident using standard of care
carotid stenting techniques (Figure 1). Given the
minimal embolic risk, distal embolic protection was
not utilized to avoid unnecessary vascular perturba-
tion. No acute changes were noted in either BP or
heart rate during the procedure, and the patient’s
neurological status was stable.
The patient was observed overnight with a
discharge BP the following morning of 125/75 mm Hg.
Heart rate remained unchanged from baseline values
at 61 beats/min. Between 1 and 6 months following
his procedure, the patient recorded daily home BP
readings with a mean of 133/86 mm Hg (range 107 to
159 mm Hg/66 to 101 mm Hg). He had no evidence
of neurological alteration, and at his most recent
follow-up visit (217 days post-procedure), his ofﬁce
BP demonstrated a sustained reduction to 138/74
mm Hg. The patient reports excellent health with
no clinical adverse events. Temporal trends in
ofﬁce-based BP measurements, home BP measure-
ments, and 24-h ambulatory BP monitoring from
screening to 217 days post-procedure also showed
improvement. Follow-up duplex ultrasound imaging
of the ipsilateral carotid artery revealed stable device
position and no evidence of trauma, stenosis, or
elevated velocities within the treated vessel.The CALM-FIM study is a safety study planning to
enroll 20 patients in the United States and 20 in
Europe. The risk-beneﬁt analysis and subsequent
pivotal trial design will need to address the inherent
risk of carotid arterial access and concerns regarding
placement of a chronic implant in this vessel. How-
ever, the new FDA pathway for this type of complex
potential innovation hopefully represents a positive
change in the bureaucratic milieu.*Chandan M. Devireddy, MD
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